A Phase 1 interventional study of Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) and Kasai Portoenterostomy in Biliary Atresia, Kasai Portoenterostomy and Mesenchymal Stem Cell Transplantation, sponsored by Universitas Diponegoro. Not yet recruiting at 1 site in Indonesia. Open to participants aged 0 Days to 90 Days. Per ClinicalTrials.gov, last updated 2025-06-08.
Sponsored by Universitas Diponegoro · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial with historical control is to evaluate whether umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy can improve clinical outcomes in infants with biliary atresia undergoing Kasai surgery before 90 days of age.
The main questions it aims to answer are:
Does UC-MSC therapy improve liver function parameters (bilirubin, albumin, liver enzymes, coagulation profile)? Does UC-MSC therapy reduce complications such as anemia, ascites, jaundice, and improve PELD scores? Does UC-MSC therapy improve overall survival compared to standard Kasai surgery alone? Researchers will compare the group receiving UC-MSC in 2025-2027 with a historical control group of patients who previously underwent Kasai surgery without UC-MSC therapy.
Participants will:
Undergo preoperative evaluation, including laboratory and imaging tests. Receive Kasai surgery combined with intraoperative trans-portal vein injection of 20 million UC-MSCs.
Be monitored postoperatively through serial laboratory tests, imaging (Fibroscan), and clinical assessments at scheduled intervals.
Be followed up for potential serious adverse events and survival outcomes.
78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.
This study's planned enrollment of 14 is below the median of 45 across 43 interventional studies indexed under Biliary Atresia.
Browse Biliary Atresia studies →Universitas Diponegoro is the lead sponsor of 23 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group are infants diagnosed with biliary atresia who undergo Kasai portoenterostomy before 90 days of age. During the operation, they receive intraoperative trans-portal vein injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) at a dose of 20 million cells diluted in 5 mL autologous plasma.
Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) · Procedure: Kasai Portoenterostomy
Participants in this group are historical patients who previously underwent Kasai portoenterostomy before 90 days of age at the same institution but did not receive UC-MSC therapy. Data for this group is collected retrospectively.
Procedure: Kasai Portoenterostomy
Intraoperative trans-portal vein injection of 20 million mesenchymal stem cells derived from umbilical cord tissue, suspended in 5 mL autologous plasma.
Surgical procedure to create a portoenterostomy for biliary drainage in infants with biliary atresia.
Serum Albumin Level
Measurement of serum albumin as marker of liver synthetic function
Time frame: Baseline (Pre-op), 4 weeks, 6 weeks, 12 weeks, 24 weeks, and 12 months post-operation
Total Bilirubin Level
Measurement of bilirubin levels (total, direct, indirect)
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Gamma Glutamyl Transferase (GGT)
Measurement of liver enzyme levels
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Alanine Aminotransferase (ALT)
Liver injury marker
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Aspartate Aminotransferase (AST)
Liver injury marker
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Prothrombin Time (PT), aPTT, INR
Coagulation parameters
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Alpha Fetoprotein (AFP)
Tumor marker
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Alkaline Phosphatase (ALP)
Liver and bone function marker
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Lactate Dehydrogenase (LDH)
Tissue injury marker
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Anemia Status
Clinical and laboratory evaluation of anemia
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Ascites
Clinical evaluation via physical exam and ultrasound
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Jaundice Status
Clinical and laboratory bilirubin assessment
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Pediatric End-Stage Liver Disease (PELD) Score
Disease severity scoring system
Time frame: Baseline, 4 weeks, 6 weeks, 12 weeks, 24 weeks, 12 months
Overall Survival (OS)
Survival rate since intervention
Time frame: From the surgery date up to the end of the study (12 months maximum follow-up)
Plan to share: No — There is no plan to make IPD available. The individual participant data will not be shared due to privacy concerns and ethical considerations related to the protection of identifiable health information of pediatric patients. Data sharing is also restricted by institutional policy and local regulations.
No publications or documents are linked to this record.
Start is estimated for Jun 2025; primary completion for Apr 2026, 10 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitas Diponegoro